Patents by Inventor Carolyn Jodka

Carolyn Jodka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hybrid polypeptides with selectable properties
    Publication number: 20060293232
    Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: August 17, 2005
    Publication date: December 28, 2006
    Applicant: Amylin Pharmaceuticals, Inc.
    Inventors: Odile Levy, Michael Hanley, Carolyn Jodka, Diana Lewis, Christopher Soares, Soumitra Ghosh, Lawrence D'Souza, David Parkes, Christine Mack
  • Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
    Publication number: 20060135747
    Abstract: The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use.
    Type: Application
    Filed: December 12, 2005
    Publication date: June 22, 2006
    Inventors: Odile Levy, Carolyn Jodka, Soumitra Ghosh, David Parkes, Richard Pittner, Lawrence D'Souza, John Ahn, Kathryn Prickett, Jonathan Roth, Sean Adams
  • Pancreatic polypeptide family motifs and polypeptides comprising the same
    Publication number: 20060094653
    Abstract: The present invention relates to novel Pancreatic Polypeptide Family (“PPF”) polypeptides. The PPF polypeptides of the invention generally include at least two PPF motif, have at least 50% sequence identity to PYY (3-36) over its length and will generally retain, at least in part, a biological activity of a PP, PYY or NPY. Preferred PPF polypeptides of the invention are those having a potency in one of the assays described herein (preferably food intake, gastric emptying, pancreatic secretion, or weight reduction assays) which is greater than the potency of PP, NPY, PYY, or PYY(3-36) in that same assay. In one aspect, the PPF polypeptides of the invention include novel PYY analog polypeptides. In another aspect, the PPF polypeptides of the invention include PPF chimeric polypeptides including a fragment of a PP family polypeptide linked to a second PP family polypeptide, wherein each of the first and second fragments includes a PPF motif.
    Type: Application
    Filed: February 11, 2005
    Publication date: May 4, 2006
    Inventors: Odile Levy, Carolyn Jodka, Soumitra Ghosh, David Parkes, Richard Pittner, Lawrence D'Souza, John Ahn, Kathryn Prickett
  • Hybrid polypeptides with selectable properties
    Publication number: 20060094652
    Abstract: The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
    Type: Application
    Filed: February 11, 2005
    Publication date: May 4, 2006
    Inventors: Odile Levy, Michael Hanley, Carolyn Jodka, Diana Lewis, Christopher Soares, Soumitra Ghosh, Lawrence D'Souza, David Parkes, Christine Mack